Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Mara PersanoMargherita RiminiToshifumi TadaGoki SudaShigeo ShimoseMasatoshi KudoFederico RossariChanghoon YooJaekyung CheonFabian FinkelmeierHo Yeong LimJosé PresaGianluca MasiFrancesca BergamoElisabeth AmadeoFrancesco VitielloTakashi KumadaNaoya SakamotoHideki IwamotoTomoko AokiHong Jae ChonVera HimmelsbachMassimo Alberto IavaroneGiuseppe CabibboMargarida MontesFrancesco Giuseppe FoschiCaterina VivaldiCaterina SoldàTakuya ShoTakashi NiizekiNaoshi NishidaChristoph SteupMariangela BruccoleriMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataAtsushi HiraokaFujimasa TadaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboMichitaka ImaiHisashi KosakaAtsushi NaganumaYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaSilvia FotiSilvia CameraFabio PiscagliaMario ScartozziStefano CascinuAndrea Casadei-GardiniPublished in: Targeted oncology (2024)
As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.